Cargando…

Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model

Aneustat (OMN54) is a multivalent, botanical anticancer candidate therapeutic. A recent Phase‐I clinical trial has indicated that it is well tolerated by patients and has immunomodulatory activity. In our study, using in vitro and in vivo prostate cancer models, we investigated Aneustat with regard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Sifeng, Xue, Hui, Dong, Xin, Lin, Dong, Wu, Rebecca, Nabavi, Noushin, Collins, Colin C., Gleave, Martin E., Gout, Peter W., Wang, Yuzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001442/ https://www.ncbi.nlm.nih.gov/pubmed/29441566 http://dx.doi.org/10.1002/ijc.31310

Ejemplares similares

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient‐derived, advanced prostate cancer tissue xenograft model
por: Qu, Sifeng, et al.
Publicado: (2013)

Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
por: Qu, Sifeng, et al.
Publicado: (2018)

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer
por: Choi, Stephen Yiu Chuen, et al.
Publicado: (2018)

Heels: Et Id Omne Genus
por: Pratt, Ben. H.
Publicado: (1879)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Contraceptives Are Also Drugs
por: Jankie, Satish, et al.
Publicado: (2023)

On the mechanism of tumor cell entry of aloe‐emodin, a natural compound endowed with anticancer activity
por: Pecere, Teresa, et al.
Publicado: (2021)

Bepridil exhibits anti‐leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia
por: Baldoni, Stefano, et al.
Publicado: (2018)

CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
por: Anderson, Enyia R., et al.
Publicado: (2022)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
por: Hermus, Merel, et al.
Publicado: (2022)

On The Ambiguity Of The Solution Of The Muskhelishvili-omnes Integral Equation
por: Truong, T N
Publicado: (2001)

Non Omnes Eadem Mirantur Ament Que
Publicado: (1868)

Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts
por: Nabavi, Noushin, et al.
Publicado: (2018)

Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
por: Pan, Zhenyu, et al.
Publicado: (2016)

Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo
por: Liu, Xuejiao, et al.
Publicado: (2019)

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer
por: Lin, Dong, et al.
Publicado: (2017)

Recent advances in network simulation: the OMNeT++ environment and its ecosystem
por: Virdis, Antonio, et al.
Publicado: (2019)

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii
por: Michaeli, Janna, et al.
Publicado: (2022)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

Use of thermo‐coagulation as an alternative treatment modality in a ‘screen‐and‐treat’ programme of cervical screening in rural Malawi
por: Campbell, Christine, et al.
Publicado: (2016)

Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma
por: Wilkinson, Michelle J., et al.
Publicado: (2016)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women
por: Gultekin, Murat, et al.
Publicado: (2017)

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100
por: De Santo, Carmela, et al.
Publicado: (2017)

Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study
por: Sun, Zimin, et al.
Publicado: (2018)

Near‐infrared photoimmunotherapy targeting EGFR—Shedding new light on glioblastoma treatment
por: Burley, Thomas A., et al.
Publicado: (2018)

The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model
por: Papaevangelou, Efthymia, et al.
Publicado: (2018)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

Cervical cancer risk in HPV‐positive women after a negative FAM19A4/mir124‐2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow‐up
por: De Strooper, Lise M.A., et al.
Publicado: (2018)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
por: Mondal, Susmita, et al.
Publicado: (2018)

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
por: Li, Jingmei, et al.
Publicado: (2018)

Screen‐detected and interval colorectal cancers in England: Associations with lifestyle and other factors in women in a large UK prospective cohort
por: Blanks, Roger, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1034qof0savhtb6gkntgagrb4p